撰文丨王聪 编辑丨王多鱼 排版丨水成文 早在 20 世纪初， 威廉·科利 （William Coley） 率先通过癌症患者肿瘤内和全身注射培养的细菌，证明了细菌癌症免疫疗法的有效性和应用价值。如今，通过膀 胱内给药的 卡介苗 （BCG， 牛分枝杆菌的减毒活菌株 ） ，成为治疗非肌层浸润性膀胱癌的标准疗法，也是唯一获得美国 FDA 批准的细菌癌症疗法。 然而，将通过基因工程改造以表达肿瘤抗原的细菌作为癌症治疗性疫苗，其治疗效果喜忧参半，其中的细胞学机制仍有待揭示。 2025 年 6 月 5 日，加州大学伯克利分校的研究人员在 Cell 子刊 Immunity 上发表了题为： Cellular mechanisms underlying beneficial versus detrimental effects of bacterial antitumor immunotherapy 的研究论文。 该研究揭示了 细菌抗肿瘤免疫疗法 有益作用 （抗肿瘤） 与有害作用 （促肿瘤） 的细胞学机制。 出乎意料的是，单独瘤内注射 （i.t.） 该李斯特菌株 （Lm） ，可招募中性粒细胞进入肿瘤，使其转化为免疫抑制表型 ，形 ...

Core Insights - Academy Sports + Outdoors is committed to expanding its presence by opening 20-25 new stores in fiscal 2025, having recently opened two new locations and planning another in Morgantown, W.Va [1][4] - The company has surpassed 300 total stores as of Q1 2025, reinforcing its mission to provide quality sporting goods and outdoor gear to families across the United States [1][10] Expansion Plans - In 2023, Academy opened 14 new stores across six states, followed by 16 new stores in 2024 across ten states, including its first locations in Ohio [4] - As of 2025, Academy has opened 7 new stores in six states, marking its first entries in Pennsylvania and Maryland [4] Community Engagement - Academy celebrated new store openings by hosting donation shopping sprees with local non-profits, enhancing community involvement and support [3][4] - The company's donations have positively impacted local communities by providing essential equipment and promoting youth participation in sports [4] Product Offering - Each Academy store offers a wide range of products including apparel, footwear, sports equipment, and outdoor gear from top national brands at competitive prices [2][5] - Academy also features exclusive private label brands that provide quality outdoor apparel and equipment [6] Customer Experience - The company provides free services such as grill and bike assembly, and offers a rewards program, myAcademy, which includes various customer benefits [8][9]

撰文丨王聪 编辑丨王多鱼 排版丨水成文 卡介苗 （BCG） ，是一种由减毒 牛分枝杆菌悬浮液制成的活菌疫苗，被用于预防 肺结核 。此外，它还具有增强巨噬细胞活性及其杀灭肿瘤细胞的能力，活化 T 淋巴细胞，增强机体细胞免疫的功能，因此，还作为治疗 膀胱癌 的免疫疗法。 当通过静脉注射给药时，卡介苗会重新编程骨髓中的造血干细胞/祖细胞 （HSPC） ，从而对感染产生异源性保护作用。但目前尚不清楚膀胱内给药卡介苗的抗肿 瘤作用是否与其对 HSPC 的重编程有关。 2025 年 5 月 29 日，威尔康奈尔医学院的研究人员在 Cell 子刊 Cancer Cell 上发表了题为： Microbial cancer immunotherapy reprograms hematopoiesis to enhance myeloid-driven anti-tumor immunity 的研究论文。 该研究表明，微生物癌症免疫疗法—— 卡介苗 ，通过重编程的造血干细胞/祖细胞 （HSPC） ，增强抗肿瘤免疫。 经卡介苗重编程的造血干细胞/祖细胞 （HSPC） 足以通过生成中性粒细胞、单核细胞和树突状细胞来增强抗肿瘤免疫，这 ...

Protara Therapeutics (TARA) FY Conference Summary Company Overview - **Company**: Protara Therapeutics - **Focus**: Development of innovative therapies for oncology, specifically targeting non-muscle invasive bladder cancer (NMIBC) with their lead program, TAR-002 Key Points and Arguments Product Development and Mechanism of Action - **TAR-002**: An investigational, genetically distinct strain of *Streptococcus pyogenes* designed to retain immune-stimulating properties through a proprietary manufacturing process [3][4] - **Comparison with BCG**: - Both TAR-002 and BCG are bacterial immune potentiators that drive a TH1 pro-inflammatory response, critical for antitumor immunity [5] - TAR-002 acts as a TLR2 agonist, while BCG is a TLR4 agonist, leading to significantly stronger tumor cell killing and higher upregulation of pro-inflammatory cytokines like TNF-alpha and interferon-gamma [6] - TAR-002 downregulates IL-8, which is associated with bladder cancer recurrence, contrasting with BCG's upregulation of IL-8 [7] Clinical Data and Efficacy Expectations - **Durable Responses**: Nonclinical studies show around 70% of mice remain cancer-free at the 60-day mark, indicating potential for durable clinical responses [7] - **Efficacy Benchmarks**: - A competitive complete response rate (CRR) of 30% is needed to be considered viable, with 40% being competitive and 50% considered best-in-class [12][13] - Initial data suggests a CRR of 63% at six months and 43% at twelve months in BCG-naive patients, with a total CRR of 76% [41] Enrollment and Market Strategy - **Enrollment Progress**: Enrollment is progressing well, with 30 sites in the US and approvals in Japan and China, aiming for full enrollment by spring 2026 [19][20] - **Patient Population**: The study is expected to have a similar split of 75% CIS and 25% concomitant papillary patients, consistent with other studies in this patient population [23][22] Competitive Landscape and Market Opportunity - **Market Size**: The addressable market is estimated at around $5 billion, with a significant number of patients seeking to avoid cystectomy [26] - **Treatment Sequencing**: Future treatment strategies may involve sequencing immune potentiators and cytotoxic drugs, enhancing the potential for TAR-002 in the treatment landscape [26] Regulatory and Development Plans - **FDA Engagement**: Plans to engage with the FDA regarding registrational studies for TAR-002, particularly in the BCG-naive setting, acknowledging the need for alternative treatment options [43][44] - **Comparative Studies**: Proposals to use chemotherapy as a comparator in studies, reflecting real-world treatment practices [46] Upcoming Catalysts - **Key Data Releases**: Anticipated data on 25 BCG unresponsive patients by the end of the year, along with updates on other ongoing studies [50][51] Additional Important Insights - **Tolerability and Administration**: TAR-002 is noted for its favorable tolerability profile, which may facilitate its adoption in community settings where treatment disruptions are less feasible [37][38] - **Long-term Development**: The company aims to position TAR-002 as a viable alternative to BCG, especially for patients who cannot access or tolerate standard BCG therapy [42][44] This summary encapsulates the critical insights from the Protara Therapeutics conference, highlighting the company's strategic direction, product differentiation, and market potential in the oncology space.

Core Insights - AstraZeneca's Imfinzi receives positive recommendation from the European Medicines Agency for bladder cancer treatment [1][2][3] - The recommendation is based on the phase III NIAGARA study, showing a 32% reduction in disease progression risk [3] - Imfinzi is already approved in the U.S. for a similar indication, marking a significant advancement in immunotherapy for muscle-invasive bladder cancer [4] Regulatory Developments - Imfinzi is recommended for use in combination with gemcitabine and cisplatin as a neoadjuvant treatment for muscle-invasive bladder cancer [2] - Regulatory applications for Imfinzi in bladder cancer are under review in Japan and other countries [8] Financial Performance - AstraZeneca's stock has increased by 7.5% year-to-date, contrasting with a 5.7% decline in the industry [5] - Imfinzi generated sales of $1.26 billion in Q1 2025, reflecting a 16% increase driven by demand in lung and liver cancer indications [10] Ongoing Research - Additional studies are underway for Imfinzi targeting other cancer indications, reinforcing its role as a key revenue driver for AstraZeneca's oncology portfolio [10] - The phase III POTOMAC study demonstrated significant improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer patients [9]

以下文章来源于电子开发学习 ，作者小马哥 电子开发学习 . 每日定期推送电子设计相关的学习例程，包括原理图设计、Layout、软件设计等相关内容，也会不定期 推送各种电子、单片机相关软件的教程。 极致性价比AI模块 ，国内对接豆包大模型，支持客户定制智能体。毛绒玩具、桌面机器人、儿童故事机等应 用场景均支持定制，感兴趣来聊 有个粉丝朋友特别喜欢看我拆解，他淘了一个稀奇古怪的东西寄给我让我拆解。 扫码加我本人微信 拿到之后我做了一番清洗，才开始拍照。看正面的面板，看不出是啥产品。 但是看顶部的接口，我感觉这像是一个充电宝。 一看背面的名牌我彻底懂了。原来果然是一个充电宝，还是非卖品，我这人有一个爱好，特别喜欢 学外语，现在看来，一切都没白学，总有一天会派上用场的。 拆解一看内部确实像经历了 14 年岁月的洗礼，看着挺脏的。但是 U1S1 ，这个板子看着设计得 还不错。 左边是输入输出接口，中间的是控制芯片，右边是电池管理芯片。板子右边上下边缘看起来焊接了 锂电池的镍片。 把底壳也拆掉，看到电路板下面的 3 颗 18650 电池了。说实话，我是没想到，也没见过锂电池 能腐蚀成这 13 样，真的是出离我的认知了，猛 ...